Landos Biopharma Announces the Appointment of Tim M. Mayleben to its Board of Directors

Rhea-AI Summary

Landos Biopharma (NASDAQ: LABP) has announced the appointment of Tim M. Mayleben to its Board of Directors. With over 20 years in the life sciences sector, Mayleben brings a wealth of experience in leading development and business strategies. He previously served as CEO of Esperion Therapeutics, where he directed the launch of Nexletol™/Nexlizet™. Mayleben will also chair the Compensation Committee and serve on the Audit Committee, aiming to leverage his expertise to advance Landos' autoimmune pipeline, which includes innovative therapies targeting conditions like ulcerative colitis and Crohn’s disease.

Positive

• Tim Mayleben's extensive experience in the biotech industry could bring fresh perspectives and strategic insights to Landos.
• His previous success in leading therapeutic development and commercialization may enhance Landos' capabilities in advancing its drug pipeline.

Negative

• Concerns over continuity and experience gaps may arise due to the recent management change.

BLACKSBURG, Va., May 19, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced the appointment of Tim M. Mayleben to its Board of Directors. Mr. Mayleben joins Landos with more than 20 years of executive experience leading development activities as well as successfully spearheading clinical and business strategies within the life sciences industry.

“We are pleased to introduce Tim as the newest Board member, Compensation Committee Chair and member of the Audit Committee,” commented Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer of Landos. “Over the course of his impressive career, Tim has successfully brought an innovative therapeutic through development, regulatory approval and commercialization and led business strategies for multiple biotech and pharmaceutical companies. We look forward to leveraging his proven track record as a business veteran in biotech as Landos expands and advances its inflammation and immunology pipeline.”

“I am thrilled to join Landos’ Board of Directors and have the opportunity to work alongside its members as well as the management team,” said Mr. Mayleben. “I am excited to apply my experience in leading development and business activities within the healthcare industry to support and advise Landos as we continue to make great strides advancing our autoimmune pipeline that has the potential to significantly improve the lives of millions of patients.”

Mr. Mayleben was most recently the President, CEO and Director of Esperion Therapeutics, Inc., a pharmaceutical company focused on the development and commercialization of therapies for the treatment of patients with elevated levels of LDL-cholesterol. In this role, he oversaw the development, strategy and commercial product launch of Nexletol™/Nexlizet™, as well as initiated collaborations with key commercial and development partners. Mr. Mayleben has more than two decades of executive leadership experience in the life sciences industry including as former President, CEO and Director of Vericel Corporation (formerly Aastrom Biosciences, Inc.), former President, COO and Board member of Virtual Radiologics (formerly Nighthawk Radiology Holdings, Inc.), and former COO and CFO of the original Esperion Therapeutics, Inc. until its acquisition by Pfizer, Inc. (NYSE: PFE) in 2004. Mr. Mayleben also serves as an Independent Board member of Marinus Pharmaceuticals (NASDAQ: MRNS) and Kaleo, Inc. where he also serves as non-executive Chairman. Mr. Mayleben earned an M.B.A., with distinction, from the J.L. Kellogg Graduate School of Management at Northwestern University, and a B.B.A. from the University of Michigan, Ross School of Business.

About Landos Biopharma

Landos Biopharma is a clinical-stage biopharmaceutical company utilizing its LANCE A.I. platform to discover and develop novel oral therapeutics for patients with autoimmune diseases. LANCE has discovered new mechanisms of action, including the LANCL2, NLRX1 and PLXDC2 immunometabolic pathways. Landos Biopharma has 17 active development programs targeting these novel pathways at the interface of immunity and metabolism. Lead asset omilancor is a novel gut-restricted small molecule drug candidate for the treatment of ulcerative colitis, Crohn’s disease and Eosinophilic Esophagitis that targets the LANCL2 pathway. NX-13 is a novel, gut-restricted small molecule drug candidate for the treatment of inflammatory bowel disease, that targets the NLRX1 pathway. Additional candidates are in development for the treatment of lupus nephritis, rheumatoid arthritis, multiple sclerosis, and diabetes. For more information, please visit www.landosbiopharma.com.

Contacts:

Michael K. Levitan (investors)
Solebury Trout
646-378-2920
mlevitan@soleburytrout.com

Hannah Gendel (media)
Solebury Trout
646-378-2943
hgendel@soleburytrout.com

 

FAQ

Who is Tim M. Mayleben and what is his role at Landos Biopharma?

Tim M. Mayleben has been appointed to Landos Biopharma's Board of Directors, where he will also chair the Compensation Committee and sit on the Audit Committee.

What is Tim Mayleben's experience prior to joining Landos Biopharma?

Before joining Landos, Mayleben served as President and CEO of Esperion Therapeutics, overseeing significant development and commercialization efforts.

How might the appointment of Tim Mayleben impact Landos Biopharma's business strategies?

His experience in the biotech field could strengthen Landos' strategic direction and enhance its ability to advance its autoimmune pipeline.

What are the main therapeutic focuses of Landos Biopharma?

Landos Biopharma focuses on developing novel oral therapeutics for autoimmune diseases, particularly targeting ulcerative colitis and Crohn’s disease.